Background/Aim:
Ultra-rare disorders (URDs) have been defined by a prevalence of less than 1 per 50,000 persons. Little is known about the current and future budget impact of ultra-orphan drugs, however. The goal of this study was therefore to conduct a budget impact analysis (BIA) of drugs for ultra-rare non-oncological diseases in Europe.
Methods:
For purposes of this analysis, the BIA had a time horizon of 10 years (from 2012 to 2021) and adopted the perspective of all European payers in combination. The estimate was based on prevalence data for URDs for which patented drugs are currently available and for which drugs are in clinical development and hence may be expected to be launched in the foreseeable future.
Key Assumptions and Inputs:
Time horizon: 10 years (2012 to 2021) Perspective: payer's perspective Scope: European countries (EU and non-EU) Cutoff prevalence rate for URDs: 1:50,000 (0.002%) Source of patent expiry dates: Medtrack database Market exclusivity periods: assumed to be 10 years Source of pipeline drugs: Medtrack database Future sales of pipeline URD drugs were estimated based on the relationship between annual per-patient drug costs and prevalence for approved drugs.
Sensitivity analysis: univariate sensitivity analyses and a worst-case and best-case scenario analysis, applying extreme values of the two most influential variables as identified in the sensitivity analysis. 
Results:
A total of 18 drugs under patent protection or orphan drug designation for non-oncological URDs were identified. Furthermore, 29 ultra-orphan drugs for nononcological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be €15,660 and €4,965 million for approved and pipeline ultra-orphan drugs, respectively (total: €20,625 million). Relative to total pharmaceutical expenditures in Europe, spending on ultra-orphan drugs is estimated to be at 0.7% at present and expected to increase to 1.6% in 2021. 
Conclusions:
The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for URDs. Continuous monitoring of the budget impact as an input to rational policy making is recommended. 
